Answers are grounded in this paper and cite their sources.
In vitro study demonstrates xanthomicrol shifts the ERα/ERβ balance toward a less aggressive phenotype in SKOV-3 ovarian cancer cells, suggesting potential to mitigate disease progression.
studies are warranted to determine if this phenotypic shift can effectively mitigate EOC progression and clinical recurrence.
No takes yet. Share an insight, caveat, or question.
Santos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: